سعر مارتافيفا 2/0.03مجم 21 قرص 2024

Combined oral contraceptive: Dienogest 2 mg / ethinylestradiol 0.03 mg tablets, pack of 21 tablets.

• Oral contraception.Population: Women of reproductive ageHealth Products Regulatory Authority (HPRA), Ireland
• Treatment of moderate acne after failure of suitable topical therapies or oral antibiotic treatment in women who elect to use an oral contraceptive.Population: Women who choose oral contraceptionHealth Products Regulatory Authority (HPRA), Ireland

• Most commonly reported adverse reactions (1% or more of users): abdominal pain and breast pain. Severe adverse reactions are arterial and venous thromboembolism.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Presence or risk of venous thromboembolism (current or past VTE such as DVT or PE, hereditary or acquired predisposition, major surgery with prolonged immobilisation, or multiple risk factors).International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Presence or risk of arterial thromboembolism (current or past myocardial infarction, angina, stroke or TIA, hereditary or acquired predisposition, migraine with focal neurological symptoms, diabetes with vascular symptoms, severe hypertension, severe dyslipoproteinaemia).International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Presence or history of severe hepatic disease while liver function values have not returned to normal; presence or history of liver tumours.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Any CHC increases the risk of venous thromboembolism compared with non-use; an estimated 8-11 per 10,000 women using a dienogest/ethinylestradiol CHC develop VTE in one year, versus about 6 with low-dose levonorgestrel CHCs and about 2 in non-users.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• An increased risk of arterial thromboembolism (myocardial infarction, stroke) is associated with CHC use; risk factors include smoking (especially over 35 years), hypertension, obesity and age.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• A meta-analysis reported a slightly increased relative risk (RR 1.24) of breast cancer diagnosis in current COC users, returning gradually to baseline within 10 years after stopping.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Hepatic enzyme inducers (e.g. phenytoin, carbamazepine, barbiturates, primidone, rifampicin, St John's wort)Increased clearance of sex hormones may cause breakthrough bleeding and contraceptive failure; use a barrier method during the inducer and for 28 days after stopping it.Health Products Regulatory Authority (HPRA), Ireland
• Ombitasvir/paritaprevir/ritonavir and dasabuvir; glecaprevir/pibrentasvirRisk of ALT elevations; contraindicated; switch to an alternative contraceptive method before starting and restart about 2 weeks after completing the regimen.Health Products Regulatory Authority (HPRA), Ireland
• Strong or moderate CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, fluconazole, diltiazem, erythromycin)May increase plasma concentrations of the estrogen and/or progestogen.Health Products Regulatory Authority (HPRA), Ireland

• Not indicated during pregnancy; if pregnancy occurs during use, stop further intake. Epidemiological studies have shown neither an increased risk of birth defects in children of women who used CHCs before pregnancy nor a teratogenic effect when taken inadvertently during early pregnancy.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Combined oral contraceptives may reduce the quantity and change the composition of breast milk; their use is generally not recommended until the mother has completely weaned her child. Small amounts of the steroids and/or metabolites may pass into milk.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

English text not available for this section.